A Belgian Postmarketing Study of Terazosin - for the Treatment of Benign Prostate Hypertrophy (bph)
(1995) Acta Therapeutica — Vol. 21, n° 3-4, p. 257-269 (1995)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- The safety and efficacy of treatment with terazosin for 6-12 months was assessed by 147 general practitioners in 805 men (mean age: 65 years) with symptomatic BPH. Primary efficacy variables were peak urinary flow rate, total International Prostate Symptom Score (I-PSS) and quality of life related to urinary symptoms. Safety was evaluated based on blood pressure, pulse rate and reports of adverse events. After a run-in period, terazosin was given in an initial dose of 1 mg once daily for 3 days and increased, according to blood pressure response and investigator's judgement, to a maximum dose of 10 mg/day. After 6 months of treatment improvement in total I-PSS symptom score from baseline of at least 30 % was observed in 89 % of patients. On completion of the study, the I-PSS quality of life score and peak urinary flow rate showed significant improvement compared with baseline. Mean pulse rate did not change over the whole observation period. In normotensive patients small, clinically insignificant decreases in blood pressure occurred. Adverse events were recorded in 111 patients (14%) of which the most common were dizziness (4.6%) and hypotension (4.3%). Only 5% of the patients discontinued the study due to adverse events. This report supports the efficacy and good toleration of terazosin in the treatment of BPH in general practice, previously reported in placebo controlled studies.
- Affiliations
Citations
Cauchie, P., Croons, AM., & Hubloux, A. (1995). A Belgian Postmarketing Study of Terazosin - for the Treatment of Benign Prostate Hypertrophy (bph). Acta Therapeutica, 21(3-4), 257-269. https://hdl.handle.net/2078.5/65239 (Original work published 1995)